Share Price and Basic Stock Data
Last Updated: December 25, 2025, 4:13 am
| PEG Ratio | -9.73 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Archean Chemical Industries Ltd operates within the chemicals sector, focusing on inorganic chemicals. As of now, the company’s stock price is ₹524, with a market capitalization of ₹6,466 Cr. Over the years, Archean has demonstrated a robust trajectory in sales, which stood at ₹1,441 Cr for the fiscal year ending March 2023, a significant rise from ₹1,130 Cr in FY 2022. However, the company reported a decline in sales to ₹1,330 Cr for FY 2024, followed by a further drop to ₹1,014 Cr projected for FY 2025. Quarterly sales trends reveal fluctuations, with the highest quarterly sales of ₹413 Cr recorded in December 2023, while the lowest was ₹211 Cr in June 2024. This volatility in sales patterns indicates a sensitive market environment, affecting overall revenue stability.
Profitability and Efficiency Metrics
Archean Chemical Industries has reported varying profitability metrics over recent periods. The operating profit margin (OPM) peaked at 51% in March 2023 but subsequently declined to 28% by March 2025. The net profit for the fiscal year ending March 2023 was ₹384 Cr, which fell to ₹185 Cr in FY 2025. The company’s return on equity (ROE) is currently at 12%, while the return on capital employed (ROCE) stands at 16%, both of which are relatively low compared to industry standards. Efficiency metrics such as the cash conversion cycle (CCC) reported at 62 days suggest challenges in managing working capital. Notably, the interest coverage ratio (ICR) is exceptionally high at 43.37x, indicating strong ability to meet interest obligations, which is a positive reflection of financial health amidst fluctuating profitability.
Balance Sheet Strength and Financial Ratios
Archean’s balance sheet reflects a solid foundation with total reserves amounting to ₹1,909 Cr and borrowings of only ₹129 Cr as of September 2025. This low level of debt relative to equity, with a debt-to-equity ratio of 0.09, indicates a conservative financing approach, enhancing financial stability. The company’s book value per share has increased to ₹151.02, compared to ₹116.29 in the previous fiscal year, showcasing improved asset value. Financial ratios such as the current ratio at 3.50x and quick ratio at 2.65x signify a strong liquidity position, providing a buffer against short-term liabilities. However, the price-to-book value (P/BV) ratio of 3.41x suggests that the stock may be overvalued compared to its net assets, which could raise concerns among potential investors.
Shareholding Pattern and Investor Confidence
The shareholding structure of Archean Chemical Industries indicates a diverse investor base, with promoters holding 53.44% of the shares. Foreign institutional investors (FIIs) have gradually increased their stake to 11.16%, while domestic institutional investors (DIIs) hold 25.51%. The public shareholding stands at 9.90%, with a total of 70,852 shareholders as of September 2025. This distribution reflects a stable foundation of institutional support, which is crucial for long-term growth. However, the recent decline in public shareholding from 13.08% in September 2023 to 9.90% raises questions about retail investor confidence. Furthermore, the increase in FII participation may suggest growing interest from foreign markets, potentially signaling positive sentiment towards Archean’s future prospects.
Outlook, Risks, and Final Insight
Looking ahead, Archean Chemical Industries faces both opportunities and challenges. The strong liquidity position and low debt levels provide a solid foundation for future growth, while increasing institutional interest could enhance market confidence. However, the volatility in sales and profitability metrics raises concerns about operational efficiency and market demand. Risks include fluctuations in raw material costs and potential regulatory changes in the chemicals sector, which could impact margins. A strategic focus on enhancing operational efficiencies and stabilizing revenue streams will be essential. Should Archean successfully navigate these challenges and capitalize on market opportunities, it can enhance its competitive edge and drive sustainable growth in the future.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Fischer Medical Ventures Ltd | 2,799 Cr. | 43.2 | 125/40.8 | 139 | 5.55 | 0.01 % | 1.08 % | 0.70 % | 1.00 |
| Emmessar Biotech & Nutrition Ltd | 14.5 Cr. | 29.0 | 47.2/25.8 | 63.0 | 16.0 | 0.00 % | 12.6 % | 4.23 % | 10.0 |
| Cochin Minerals & Rutile Ltd | 207 Cr. | 264 | 356/238 | 12.3 | 211 | 3.03 % | 23.3 % | 15.0 % | 10.0 |
| Archean Chemical Industries Ltd | 6,466 Cr. | 524 | 728/408 | 31.6 | 157 | 0.57 % | 16.0 % | 12.0 % | 2.00 |
| Alufluoride Ltd | 334 Cr. | 428 | 517/376 | 16.3 | 144 | 0.70 % | 23.6 % | 20.8 % | 10.0 |
| Industry Average | 5,006.63 Cr | 544.23 | 153.55 | 160.00 | 0.49% | 13.95% | 10.65% | 7.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 400 | 293 | 365 | 382 | 343 | 290 | 413 | 283 | 211 | 238 | 243 | 322 | 279 |
| Expenses | 239 | 175 | 205 | 188 | 208 | 195 | 267 | 195 | 139 | 162 | 158 | 232 | 196 |
| Operating Profit | 161 | 119 | 160 | 194 | 135 | 96 | 146 | 88 | 73 | 76 | 84 | 90 | 83 |
| OPM % | 40% | 40% | 44% | 51% | 39% | 33% | 35% | 31% | 34% | 32% | 35% | 28% | 30% |
| Other Income | 9 | 19 | 8 | 9 | 11 | 12 | 10 | 14 | 12 | -26 | 12 | 12 | 13 |
| Interest | 39 | 35 | 19 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 |
| Depreciation | 18 | 17 | 17 | 17 | 17 | 17 | 18 | 17 | 18 | 18 | 19 | 19 | 20 |
| Profit before tax | 113 | 86 | 131 | 182 | 125 | 88 | 136 | 82 | 65 | 30 | 75 | 80 | 72 |
| Tax % | 25% | 26% | 25% | 25% | 25% | 24% | 25% | 28% | 26% | 26% | 25% | 27% | 28% |
| Net Profit | 85 | 64 | 98 | 137 | 94 | 66 | 102 | 60 | 48 | 22 | 56 | 58 | 52 |
| EPS in Rs | 8.79 | 6.63 | 7.99 | 11.12 | 7.65 | 5.39 | 8.28 | 4.83 | 3.93 | 1.77 | 4.56 | 4.72 | 4.20 |
Last Updated: August 1, 2025, 7:30 am
Below is a detailed analysis of the quarterly data for Archean Chemical Industries Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 279.00 Cr.. The value appears to be declining and may need further review. It has decreased from 322.00 Cr. (Mar 2025) to 279.00 Cr., marking a decrease of 43.00 Cr..
- For Expenses, as of Jun 2025, the value is 196.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 232.00 Cr. (Mar 2025) to 196.00 Cr., marking a decrease of 36.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 83.00 Cr.. The value appears to be declining and may need further review. It has decreased from 90.00 Cr. (Mar 2025) to 83.00 Cr., marking a decrease of 7.00 Cr..
- For OPM %, as of Jun 2025, the value is 30.00%. The value appears strong and on an upward trend. It has increased from 28.00% (Mar 2025) to 30.00%, marking an increase of 2.00%.
- For Other Income, as of Jun 2025, the value is 13.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 13.00 Cr., marking an increase of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 20.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 19.00 Cr. (Mar 2025) to 20.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 72.00 Cr.. The value appears to be declining and may need further review. It has decreased from 80.00 Cr. (Mar 2025) to 72.00 Cr., marking a decrease of 8.00 Cr..
- For Tax %, as of Jun 2025, the value is 28.00%. The value appears to be increasing, which may not be favorable. It has increased from 27.00% (Mar 2025) to 28.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 58.00 Cr. (Mar 2025) to 52.00 Cr., marking a decrease of 6.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.20. The value appears to be declining and may need further review. It has decreased from 4.72 (Mar 2025) to 4.20, marking a decrease of 0.52.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:12 am
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 439 | 566 | 608 | 741 | 1,130 | 1,441 | 1,330 | 1,014 | 1,064 |
| Expenses | 356 | 497 | 460 | 478 | 663 | 807 | 865 | 691 | 742 |
| Operating Profit | 83 | 69 | 148 | 262 | 467 | 634 | 464 | 323 | 322 |
| OPM % | 19% | 12% | 24% | 35% | 41% | 44% | 35% | 32% | 30% |
| Other Income | 6 | 121 | 8 | 14 | 13 | 44 | 47 | 9 | 48 |
| Interest | 102 | 114 | 122 | 130 | 162 | 97 | 10 | 9 | 14 |
| Depreciation | 73 | 47 | 52 | 55 | 67 | 69 | 70 | 73 | 77 |
| Profit before tax | -85 | 29 | -17 | 90 | 251 | 513 | 431 | 250 | 278 |
| Tax % | -7% | -41% | 105% | 26% | 25% | 25% | 25% | 26% | |
| Net Profit | -79 | 41 | -36 | 67 | 189 | 384 | 322 | 185 | 205 |
| EPS in Rs | -79.16 | 21.31 | -18.50 | 34.56 | 19.58 | 31.18 | 26.12 | 14.98 | 16.60 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 8% | 11% | 20% |
YoY Net Profit Growth
| Year | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 151.90% | -187.80% | 286.11% | 182.09% | 103.17% | -16.15% | -42.55% |
| Change in YoY Net Profit Growth (%) | 0.00% | -339.70% | 473.92% | -104.02% | -78.91% | -119.32% | -26.40% |
Archean Chemical Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 7 years from 2018-2019 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | -4% |
| TTM: | -10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 52% |
| 3 Years: | 5% |
| TTM: | -20% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -6% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 22% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 2:21 pm
Balance Sheet
Last Updated: December 10, 2025, 3:50 am
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 19 | 19 | 19 | 19 | 25 | 25 | 25 | 25 |
| Reserves | -38 | 24 | -12 | 55 | 243 | 1,408 | 1,682 | 1,855 | 1,909 |
| Borrowings | 968 | 754 | 854 | 904 | 897 | 69 | 39 | 108 | 129 |
| Other Liabilities | 316 | 439 | 568 | 457 | 372 | 254 | 246 | 261 | 248 |
| Total Liabilities | 1,256 | 1,237 | 1,430 | 1,434 | 1,532 | 1,756 | 1,991 | 2,249 | 2,311 |
| Fixed Assets | 940 | 914 | 882 | 1,042 | 1,086 | 1,097 | 1,086 | 1,071 | 1,107 |
| CWIP | 0 | 9 | 193 | 19 | 17 | 33 | 21 | 28 | 11 |
| Investments | 0 | 0 | 47 | 41 | 16 | 215 | 347 | 350 | 388 |
| Other Assets | 316 | 314 | 308 | 332 | 412 | 410 | 537 | 800 | 804 |
| Total Assets | 1,256 | 1,237 | 1,430 | 1,434 | 1,532 | 1,756 | 1,991 | 2,249 | 2,311 |
Below is a detailed analysis of the balance sheet data for Archean Chemical Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 25.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 25.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,909.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,855.00 Cr. (Mar 2025) to 1,909.00 Cr., marking an increase of 54.00 Cr..
- For Borrowings, as of Sep 2025, the value is 129.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 108.00 Cr. (Mar 2025) to 129.00 Cr., marking an increase of 21.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 248.00 Cr.. The value appears to be improving (decreasing). It has decreased from 261.00 Cr. (Mar 2025) to 248.00 Cr., marking a decrease of 13.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 2,311.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,249.00 Cr. (Mar 2025) to 2,311.00 Cr., marking an increase of 62.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 1,107.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,071.00 Cr. (Mar 2025) to 1,107.00 Cr., marking an increase of 36.00 Cr..
- For CWIP, as of Sep 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 28.00 Cr. (Mar 2025) to 11.00 Cr., marking a decrease of 17.00 Cr..
- For Investments, as of Sep 2025, the value is 388.00 Cr.. The value appears strong and on an upward trend. It has increased from 350.00 Cr. (Mar 2025) to 388.00 Cr., marking an increase of 38.00 Cr..
- For Other Assets, as of Sep 2025, the value is 804.00 Cr.. The value appears strong and on an upward trend. It has increased from 800.00 Cr. (Mar 2025) to 804.00 Cr., marking an increase of 4.00 Cr..
- For Total Assets, as of Sep 2025, the value is 2,311.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,249.00 Cr. (Mar 2025) to 2,311.00 Cr., marking an increase of 62.00 Cr..
Notably, the Reserves (1,909.00 Cr.) exceed the Borrowings (129.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -885.00 | -685.00 | -706.00 | -642.00 | -430.00 | 565.00 | 425.00 | 215.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 22 | 43 | 27 | 34 | 49 | 30 | 43 | 62 |
| Inventory Days | 830 | 238 | 999 | 532 | ||||
| Days Payable | 1,035 | 398 | 1,689 | 415 | ||||
| Cash Conversion Cycle | -183 | -116 | -663 | 34 | 49 | 30 | 160 | 62 |
| Working Capital Days | -70 | 0 | -38 | 22 | 50 | 41 | 54 | 92 |
| ROCE % | 3% | 13% | 24% | 39% | 46% | 27% | 16% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| DSP Small Cap Fund | 4,500,000 | 1.35 | 230.45 | 2,297,376 | 2025-10-31 05:55:09 | 95.88% |
| SBI Small Cap Fund | 4,400,000 | 0.62 | 225.32 | 4,400,000 | 2025-04-22 14:12:24 | 0% |
| SBI Multicap Fund | 4,094,476 | 0.88 | 209.68 | 4,094,476 | 2025-04-22 15:56:51 | 0% |
| Nippon India Small Cap Fund | 1,373,373 | 0.1 | 70.33 | 1,373,373 | 2025-04-22 15:56:51 | 0% |
| HDFC Multi Cap Fund | 1,054,429 | 0.27 | 54 | 1,095,175 | 2025-10-31 05:55:09 | -3.72% |
| Bandhan Small Cap Fund | 702,033 | 0.2 | 35.95 | N/A | N/A | N/A |
| HDFC Large and Mid Cap Fund | 440,359 | 0.08 | 22.55 | N/A | N/A | N/A |
| ICICI Prudential Multicap Fund | 342,211 | 0.11 | 17.52 | N/A | N/A | N/A |
| ICICI Prudential Commodities Fund | 333,388 | 0.54 | 17.07 | 233,388 | 2025-12-15 04:54:48 | 42.85% |
| ICICI Prudential Manufacturing Fund | 200,000 | 0.15 | 10.24 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 |
|---|---|---|---|---|
| FaceValue | 2.00 | 2.00 | 2.00 | 2.00 |
| Basic EPS (Rs.) | 13.13 | 25.90 | 34.66 | 18.22 |
| Diluted EPS (Rs.) | 13.12 | 25.87 | 34.59 | 18.22 |
| Cash EPS (Rs.) | 19.57 | 31.55 | 36.67 | 26.48 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 151.02 | 137.89 | 116.29 | 26.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 151.02 | 137.89 | 116.29 | 26.75 |
| Revenue From Operations / Share (Rs.) | 84.34 | 107.79 | 117.11 | 117.35 |
| PBDIT / Share (Rs.) | 28.47 | 41.00 | 55.04 | 49.78 |
| PBIT / Share (Rs.) | 22.04 | 35.30 | 49.46 | 42.84 |
| PBT / Share (Rs.) | 18.13 | 34.62 | 41.58 | 26.06 |
| Net Profit / Share (Rs.) | 13.14 | 25.85 | 31.09 | 19.54 |
| NP After MI And SOA / Share (Rs.) | 13.14 | 25.85 | 31.09 | 19.54 |
| PBDIT Margin (%) | 33.75 | 38.04 | 46.99 | 42.42 |
| PBIT Margin (%) | 26.13 | 32.75 | 42.23 | 36.50 |
| PBT Margin (%) | 21.49 | 32.11 | 35.50 | 22.20 |
| Net Profit Margin (%) | 15.57 | 23.98 | 26.54 | 16.64 |
| NP After MI And SOA Margin (%) | 15.57 | 23.98 | 26.54 | 16.64 |
| Return on Networth / Equity (%) | 8.69 | 18.74 | 26.73 | 73.02 |
| Return on Capital Employeed (%) | 12.38 | 22.67 | 38.44 | 30.43 |
| Return On Assets (%) | 6.77 | 15.51 | 21.79 | 12.29 |
| Long Term Debt / Equity (X) | 0.08 | 0.03 | 0.00 | 3.27 |
| Total Debt / Equity (X) | 0.09 | 0.03 | 0.01 | 3.28 |
| Asset Turnover Ratio (%) | 0.46 | 0.69 | 0.87 | 0.00 |
| Current Ratio (X) | 3.50 | 5.38 | 3.35 | 2.27 |
| Quick Ratio (X) | 2.65 | 4.44 | 2.37 | 1.58 |
| Inventory Turnover Ratio (X) | 0.42 | 0.32 | 0.31 | 0.00 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 17.37 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 14.23 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 0.00 | 82.63 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 0.00 | 85.77 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 43.37 | 59.80 | 6.99 | 2.97 |
| Interest Coverage Ratio (Post Tax) (X) | 25.97 | 38.70 | 4.95 | 2.16 |
| Enterprise Value (Cr.) | 6487.30 | 8283.52 | 7995.88 | 0.00 |
| EV / Net Operating Revenue (X) | 6.23 | 6.23 | 5.55 | 0.00 |
| EV / EBITDA (X) | 18.46 | 16.37 | 11.81 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 6.11 | 6.22 | 5.56 | 0.00 |
| Retention Ratios (%) | 0.00 | 82.62 | 0.00 | 0.00 |
| Price / BV (X) | 3.41 | 4.86 | 5.60 | 0.00 |
| Price / Net Operating Revenue (X) | 6.11 | 6.22 | 5.56 | 0.00 |
| EarningsYield | 0.02 | 0.03 | 0.04 | 0.00 |
After reviewing the key financial ratios for Archean Chemical Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 2.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 2.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 13.13. This value is within the healthy range. It has decreased from 25.90 (Mar 24) to 13.13, marking a decrease of 12.77.
- For Diluted EPS (Rs.), as of Mar 25, the value is 13.12. This value is within the healthy range. It has decreased from 25.87 (Mar 24) to 13.12, marking a decrease of 12.75.
- For Cash EPS (Rs.), as of Mar 25, the value is 19.57. This value is within the healthy range. It has decreased from 31.55 (Mar 24) to 19.57, marking a decrease of 11.98.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 151.02. It has increased from 137.89 (Mar 24) to 151.02, marking an increase of 13.13.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 151.02. It has increased from 137.89 (Mar 24) to 151.02, marking an increase of 13.13.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 84.34. It has decreased from 107.79 (Mar 24) to 84.34, marking a decrease of 23.45.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 28.47. This value is within the healthy range. It has decreased from 41.00 (Mar 24) to 28.47, marking a decrease of 12.53.
- For PBIT / Share (Rs.), as of Mar 25, the value is 22.04. This value is within the healthy range. It has decreased from 35.30 (Mar 24) to 22.04, marking a decrease of 13.26.
- For PBT / Share (Rs.), as of Mar 25, the value is 18.13. This value is within the healthy range. It has decreased from 34.62 (Mar 24) to 18.13, marking a decrease of 16.49.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 13.14. This value is within the healthy range. It has decreased from 25.85 (Mar 24) to 13.14, marking a decrease of 12.71.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 13.14. This value is within the healthy range. It has decreased from 25.85 (Mar 24) to 13.14, marking a decrease of 12.71.
- For PBDIT Margin (%), as of Mar 25, the value is 33.75. This value is within the healthy range. It has decreased from 38.04 (Mar 24) to 33.75, marking a decrease of 4.29.
- For PBIT Margin (%), as of Mar 25, the value is 26.13. This value exceeds the healthy maximum of 20. It has decreased from 32.75 (Mar 24) to 26.13, marking a decrease of 6.62.
- For PBT Margin (%), as of Mar 25, the value is 21.49. This value is within the healthy range. It has decreased from 32.11 (Mar 24) to 21.49, marking a decrease of 10.62.
- For Net Profit Margin (%), as of Mar 25, the value is 15.57. This value exceeds the healthy maximum of 10. It has decreased from 23.98 (Mar 24) to 15.57, marking a decrease of 8.41.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 15.57. This value is within the healthy range. It has decreased from 23.98 (Mar 24) to 15.57, marking a decrease of 8.41.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.69. This value is below the healthy minimum of 15. It has decreased from 18.74 (Mar 24) to 8.69, marking a decrease of 10.05.
- For Return on Capital Employeed (%), as of Mar 25, the value is 12.38. This value is within the healthy range. It has decreased from 22.67 (Mar 24) to 12.38, marking a decrease of 10.29.
- For Return On Assets (%), as of Mar 25, the value is 6.77. This value is within the healthy range. It has decreased from 15.51 (Mar 24) to 6.77, marking a decrease of 8.74.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.08. This value is below the healthy minimum of 0.2. It has increased from 0.03 (Mar 24) to 0.08, marking an increase of 0.05.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. It has increased from 0.03 (Mar 24) to 0.09, marking an increase of 0.06.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.46. It has decreased from 0.69 (Mar 24) to 0.46, marking a decrease of 0.23.
- For Current Ratio (X), as of Mar 25, the value is 3.50. This value exceeds the healthy maximum of 3. It has decreased from 5.38 (Mar 24) to 3.50, marking a decrease of 1.88.
- For Quick Ratio (X), as of Mar 25, the value is 2.65. This value exceeds the healthy maximum of 2. It has decreased from 4.44 (Mar 24) to 2.65, marking a decrease of 1.79.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.42. This value is below the healthy minimum of 4. It has increased from 0.32 (Mar 24) to 0.42, marking an increase of 0.10.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 17.37 (Mar 24) to 0.00, marking a decrease of 17.37.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 14.23 (Mar 24) to 0.00, marking a decrease of 14.23.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 82.63 (Mar 24) to 0.00, marking a decrease of 82.63.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 85.77 (Mar 24) to 0.00, marking a decrease of 85.77.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 43.37. This value is within the healthy range. It has decreased from 59.80 (Mar 24) to 43.37, marking a decrease of 16.43.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 25.97. This value is within the healthy range. It has decreased from 38.70 (Mar 24) to 25.97, marking a decrease of 12.73.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6,487.30. It has decreased from 8,283.52 (Mar 24) to 6,487.30, marking a decrease of 1,796.22.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 6.23. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 6.23.
- For EV / EBITDA (X), as of Mar 25, the value is 18.46. This value exceeds the healthy maximum of 15. It has increased from 16.37 (Mar 24) to 18.46, marking an increase of 2.09.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 6.11. This value exceeds the healthy maximum of 3. It has decreased from 6.22 (Mar 24) to 6.11, marking a decrease of 0.11.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 82.62 (Mar 24) to 0.00, marking a decrease of 82.62.
- For Price / BV (X), as of Mar 25, the value is 3.41. This value exceeds the healthy maximum of 3. It has decreased from 4.86 (Mar 24) to 3.41, marking a decrease of 1.45.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 6.11. This value exceeds the healthy maximum of 3. It has decreased from 6.22 (Mar 24) to 6.11, marking a decrease of 0.11.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.03 (Mar 24) to 0.02, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Archean Chemical Industries Ltd:
- Net Profit Margin: 15.57%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 12.38% (Industry Average ROCE: 13.95%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.69% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 25.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.65
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 31.6 (Industry average Stock P/E: 153.55)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 15.57%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Others | No. 2, North Crescent Road, Chennai (Madras) Tamil Nadu 600017 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ranjit Pendurthi | Managing Director |
| Mr. N R Kannan | Executive Director |
| Mr. Ravi Pendurthi | Non Independent Director |
| Mr. Subrahmanyam Meenakshisundaram | Non Independent Director |
| Ms. Padma Chandrasekaran | Independent Director |
| Mr. Chittoor Ghatambu Sethuram | Independent Director |
| Mr. Kandheri Munaswami Mohandass | Independent Director |
FAQ
What is the intrinsic value of Archean Chemical Industries Ltd?
Archean Chemical Industries Ltd's intrinsic value (as of 25 December 2025) is 478.99 which is 8.59% lower the current market price of 524.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 6,466 Cr. market cap, FY2025-2026 high/low of 728/408, reserves of ₹1,909 Cr, and liabilities of 2,311 Cr.
What is the Market Cap of Archean Chemical Industries Ltd?
The Market Cap of Archean Chemical Industries Ltd is 6,466 Cr..
What is the current Stock Price of Archean Chemical Industries Ltd as on 25 December 2025?
The current stock price of Archean Chemical Industries Ltd as on 25 December 2025 is 524.
What is the High / Low of Archean Chemical Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Archean Chemical Industries Ltd stocks is 728/408.
What is the Stock P/E of Archean Chemical Industries Ltd?
The Stock P/E of Archean Chemical Industries Ltd is 31.6.
What is the Book Value of Archean Chemical Industries Ltd?
The Book Value of Archean Chemical Industries Ltd is 157.
What is the Dividend Yield of Archean Chemical Industries Ltd?
The Dividend Yield of Archean Chemical Industries Ltd is 0.57 %.
What is the ROCE of Archean Chemical Industries Ltd?
The ROCE of Archean Chemical Industries Ltd is 16.0 %.
What is the ROE of Archean Chemical Industries Ltd?
The ROE of Archean Chemical Industries Ltd is 12.0 %.
What is the Face Value of Archean Chemical Industries Ltd?
The Face Value of Archean Chemical Industries Ltd is 2.00.